A Phase 2 interventional study of MSTT1041A and Placebo in Atopic Dermatitis, sponsored by Genentech, Inc.. Completed at 21 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 311th largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 202 in phase 2, and was the 299th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 58 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MSTT1041A
Drug: MSTT1041A
Participants will receive placebo matched to MSTT1041A
Drug: Placebo
Participants will receive subcutaneous (SC) MSTT1041A
Also known as: astegolimab
Participants will receive SC placebo
Percent Change of Total Eczema Area and Severity Index (EASI) Score
The Eczema Area and Severity Index (EASI) is a standardized instrument to evaluate the extent and severity of atopic dermatitis. An area score comprised of the percentage of skin affected by eczema for each of 4 body regions (head/neck, trunk, upper extremities, and lower extremities) is calculated with 0 = none, 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89%, and 6 = 90-100%. Severity is scored for each of the 4 body regions by the summation of the intensity scores for 4 signs (redness, thickness, scratching, and lichenification), with 0 = none/absent, 1 = mild, 2 = moderate, and 3 = severe. The minimum final EASI score is 0 and the maximum score is 72.
Time frame: Baseline, Week 16
Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1
Time frame: Baseline, Week 16
Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score
Time frame: Baseline, Week 16
Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS)
The Peak Pruritis Numerical Rating Scale (NRS) is a single-item patient-reported outcome (PRO) of itch severity rated on a scale of 0-10, with 0 = no itch and 10 = worst itch imaginable for the prior 24-hour period.
Time frame: Baseline, Week 16
Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement
Time frame: Baseline, Week 16
Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD)
SCORAD is a tool used to assess the extent and severity of eczema based on three aspects of disease severity: extent, intensity, and a subjective (PRO) symptoms. A total score (0-103) is calculated, with higher scores indicating a higher extent and severity of symptoms.
Time frame: Baseline, Week 16
Percentage of Participants With Adverse Events (AE)
Time frame: Up to Week 24
Serum Concentrations of MSTT1041A
Time frame: At pre-defined intervals from baseline up to Week 24
Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)
Time frame: Up to Week 24
| Milestone | Placebo | Treatment |
|---|---|---|
| Started | 32 | 33 |
| Completed | 23 | 26 |
| Not completed | 9 | 7 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Adverse event | 0 | 1 |
The Eczema Area and Severity Index (EASI) is a standardized instrument to evaluate the extent and severity of atopic dermatitis. An area score comprised of the percentage of skin affected by eczema for each of 4 body regions (head/neck, trunk, upper extremities, and lower extremities) is calculated with 0 = none, 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89%, and 6 = 90-100%. Severity is scored for each of the 4 body regions by the summation of the intensity scores for 4 signs (redness, thickness, scratching, and lichenification), with 0 = none/absent, 1 = mild, 2 = moderate, and 3 = severe. The minimum final EASI score is 0 and the maximum score is 72.
| Percentage | Treatment | Placebo |
|---|---|---|
| Percent Change of Total Eczema Area and Severity Index (EASI) Score | -51.47 ± 8.639 | -58.24 ± 9.092 |
| Percentage | Treatment | Placebo |
|---|---|---|
| Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1 | 15.2 | 6.3 |
| Percentage | Treatment | Placebo |
|---|---|---|
| Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score | 27.3 | 18.8 |
The Peak Pruritis Numerical Rating Scale (NRS) is a single-item patient-reported outcome (PRO) of itch severity rated on a scale of 0-10, with 0 = no itch and 10 = worst itch imaginable for the prior 24-hour period.
| Percentage | Treatment | Placebo |
|---|---|---|
| Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS) | -31.22 ± 7.376 | -39.43 ± 7.839 |
| Percentage | Treatment | Placebo |
|---|---|---|
| Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement | -42.23 ± 8.637 | -38.87 ± 9.134 |
SCORAD is a tool used to assess the extent and severity of eczema based on three aspects of disease severity: extent, intensity, and a subjective (PRO) symptoms. A total score (0-103) is calculated, with higher scores indicating a higher extent and severity of symptoms.
| Percentage | Treatment | Placebo |
|---|---|---|
| Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD) | -35.45 ± 6.837 | -39.50 ± 7.202 |
| Participants | Treatment | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events (AE) | 14 | 18 |
| ug/mL | Treatment |
|---|---|
| Day 1 Visit 2/prior to infusion | NA ± NA |
| Week 1 Visit 3/prior to infusion | 42.6 ± 34.4 |
| Week 4 Visit 5/prior to infusion | 37.6 ± 52.5 |
| Week 8 Visit 7/prior to infusion | 36.6 ± 54.5 |
| Week 12 Visit 9/prior to infusion | 40.1 ± 60.5 |
| Week 16 Visit 11 | 38.2 ± 76.0 |
| Subject disposition - period completion/early discontinuation | 7.83 ± 151.2 |
| Participants | Treatment | Placebo |
|---|---|---|
| Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs) | 1 | 0 |
Collected over Up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/31 (0%) | 0/31 (0%) | 8/31 (25.8%) |
| Treatment | 0/34 (0%) | 1/34 (2.9%) | 3/34 (8.8%) |
| Event | Placebo | Treatment |
|---|---|---|
| Aortic aneurysmVascular disorders | 0/31 | 1/34 |
| Event | Placebo | Treatment |
|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 5/31 | 3/34 |
| NasopharyngitisInfections and infestations | 3/31 | 0/34 |
| Abdominal painGastrointestinal disorders | 2/31 | 0/34 |
| Age, Categorical(Participants) | Placebo | Treatment | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 31 | 61 |
| >=65 years | 2 | 2 | 4 |
| Age, Continuous(Years) | Placebo | Treatment | Total |
|---|---|---|---|
| Mean | 39.3 ± 14.4 | 39.7 ± 15.2 | 39.5 ± 14.7 |
| Sex: Female, Male(Participants) | Placebo | Treatment | Total |
|---|---|---|---|
| Female | 20 | 20 | 40 |
| Male | 12 | 13 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Treatment | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 30 | 30 | 60 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Treatment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 8 | 16 |
| White | 20 | 25 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm
Ran from Feb 2019 to primary completion in Mar 2020, 13 months.
Results were first posted in May 2023, 3 years 1 month after primary completion. A results delay was requested in Mar 2021.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Astegolimab